Equity Analysis: Taleo, Idenix, Community Health, Edwards Lifesciences, Ryder System
Taleo Corp. (NASDAQ:TLEO): After SuccessFactors (NASDAQ:SFSF) preannounced higher than expected Q4 revenue, BMO Capital thinks its preannouncement is positive for Taleo (NASDAQ:TLEO). The firm also reported that two smaller private HR SaaS vendors made positive comments about the sector, and BMO Capital maintains an Outperform rating on Taleo.
Idenix Pharmaceuticals Inc. (NASDAQ:IDIX): Brean Murray noted the excellent data from Gilead’s (NASDAQ:GILD) Hep-C drug which provided unprecedented efficacy and said it should generate some serious consideration as to the viability of Idenix (NASDAQ:IDIX) drug trials. Brean Murray noted Idenix inferior results and believes regulators and doctors would also and questioned whether the company’s drug would be a relevant treatment. Shares of Idenix are Sell rated while shares of Gilead remain Buy rated.
Community Health Systems, Inc. (NYSE:CYH): Credit Suisse believes Community Health expectations are low and that the Q4 report and guidance could alleviate some concerns regarding the government investigation, negative volume trends, and confusion over HITECH. Price target is $27.
Edwards Lifesciences Corp. (NYSE:EW): After Edwards Lifesciences reported lower than expected Q4 sales and CMS proposed Sapien coverage rules that would restrict adoption of the product, RBC Capital continues to see several upcoming catalysts for the stock and believes that final Sapien coverage rules will be less restrictive than CMS’ proposal. The firm maintains an Outperform rating.
Ryder System, Inc.(NYSE:R): RBC Capital reduced its target on Ryder after the company provided lower than expected 2012 EPS guidance. However, the firm thinks the stock’s valuation is attractive and it maintains an Outperform rating.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at email@example.com
To contact the editor responsible for this story: Damien Hoffman at firstname.lastname@example.org